Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) belonging to the Medical sector has declined -0.9% and closed its last trading session at $15.37.
The company reported its EPS on 11/03/2016. Currently, the stock has a 1 Year Price Target of $15.38.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2.14 respectively.
Ironwood Pharmaceuticals, Inc. on 11/03/2016 reported its EPS as $-0.23 with the analysts projecting the EPS of the stock as $-0.24. The company beat the analyst EPS Estimate with the difference of $0.01. This shows a surprise factor of 4.2%.
Many analysts have provided their estimated foresights on Ironwood Pharmaceuticals, Inc. Earnings, with 9 analysts believing the company would generate an Average Estimate of $-0.27. Whereas they predicted High and Low Earnings Estimate as $-0.19 and $-0.36 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.09.
Analysts are also projecting an Average Revenue Estimate for Ironwood Pharmaceuticals, Inc. as $69.53 Million in the Current Quarter. This estimate is provided by 9 analysts. The High Revenue estimate is predicted as 75.2 Million, while the Low Revenue Estimate prediction stands at 59.6 Million. The company’s last year sales total was 53.31 Million.
The Company got Initiated by Goldman on 21-Mar-16 to Neutral.
Insider Trades for Ironwood Pharmaceuticals, Inc. show that the latest trade was made on 14 Sep 2016 where Mcguire (Terrance G), the Director completed a transaction type “Buy” in which 166 shares were traded at a price of $0.
12 analysts projected Price Targets for Ironwood Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $20. The Low Price target projection by analysts is $8 and the Mean Price Target is $15.38.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has the market capitalization of $2.2 Billion. The company rocked its 52-Week High of $16.89 on Nov 11, 2016 and touched its 52-Week Low of $7.35 on Feb 8, 2016. The stock has Return on Assets (ROA) of -12.4 percent. Return on Equity (ROE) stands at -100.6% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 32.61 Percent. The company has Beta Value of 1.48 and ATR value of 0.67. The Weekly and Monthly Volatility stands at 3.85% and 4.46%.
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company’s first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.